Hand-foot syndrome as a predictor of better outcomes in patients treated with sunitinib

A recent study, published in the journal Advances in Medicine and Medical Research, suggests that the presence of hand-foot syndrome in patients with metastatic renal cell carcinoma (RCC) after the first cycle of treatment with sunitinib predicts longer progression-free survival. Median progression-free survival was 9.8 months in those patients who did not experience hand-foot syndrome […]

read more

ASCO GU 2019: Avelumab plus axitinib combination superior to sunitinib

The results from the following study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Dr Toni Choueiri from the Dana-Farber Cancer Institute and Harvard Medical School in Boston, USA, presented updated results from the JAVELIN Renal 101 clinical trial. The results showed that treatment with a […]

read more

ASCO GU 2019: Tivozanib effective for refractory metastatic kidney cancer

The results from the following study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Dr Brian Rini from the Cleveland Clinic Taussig Cancer Institute presented the results from a phase 3 clinical trial (TIVO-3) to compare the efficacy and safety of tivozanib to sorafenib in patients […]

read more

Potential predictive biomarker of response to VEGF treatment in metastatic kidney cancer

A recent study published on PLOS/ONE has identified three genetic mutations/alterations that are strongly predictive of progression-free survival in patients receiving first-line treatment with a vascular endothelial growth factor (VEGF) inhibitor for metastatic kidney cancer. The genes involved are TP53, wild type VHL and variants of FLT1C/C. Kidney cancer patients who did not have a mutation/alteration […]

read more

Second-line treatment with axitinib in favourable risk patients

Results from a phase 2 study to assess the activity of axitinib in patients with metastatic renal cell carcinoma (RCC) with a favourable risk (FavorAx) after having received first-line treatment with a vascular endothelial growth factor receptor (VEGFR)-directed therapy. In this study, median progression-free survival was 19 months, and the study achieved its primary endpoint based on […]

read more

Real world safety and efficacy of nivolumab for kidney cancer

A recent study reports the real-world safety and efficacy of nivolumab from metastatic renal cell carcinoma (RCC) patients on an expanded access programme in Italy. In all, 389 patients received nivolumab 3 mg/kg every other week. The objective response rate was 23.1%, and the median progression-free survival was 4.5 months. The 12-month overall survival rate […]

read more

Immunoscore system to predict kidney cancer patient outcomes

A recent study by researchers in China, and published in the Journal of Cancer, assessed the Immunoscore system to determine if it can predict survival in patients with metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKIs). The presence of various protein receptors on the cancer cells were analysed. Levels of protein receptors for […]

read more

Surgery may not be the most appropriate frontline treatment for metastatic kidney cancer

Results of the phase 3 SURTIME trial comparing pretreatment with sunitinib before nephrectomy, with immediate nephrectomy followed by sunitinib treatment were published in JAMA Oncology recently. The findings suggest that pretreating metastatic renal cell carcinoma (RCC) patients with sunitinib before surgery may lead to better or at least similar outcomes for patients compared to immediate nephrectomy. Although […]

read more

Deferred cytoreductive nephrectomy in kidney cancer fails to improve progression-free survival

Results from the phase 3 CARMENA study, published in the journal JAMA Oncology, found that pretreatment of renal cell carcinoma (RCC) patients with sunitinib followed by deferred cytoreductive nephrectomy did not improve 28-week progression-free survival rates compared with immediate nephrectomy followed by sunitinib in these patients. However, patients who received sunitinib followed by deferred cytoreductive […]

read more

Advances and next steps in kidney cancer

In an interview with OncLive, Dr Toni Choueiri from Harvard Medical School, Dana-Farber Cancer Institute in America, discusses recent progress in renal cell carcinoma (RCC) and future research in this area. Dr Choueiri talks about the breakthroughs in the treatment of patients with RCC over the last decade, such as checkpoint inhibitors, targeted agents, and combination […]

read more
Showing 51 to 60 of 71 results
  TOP